Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
종목 코드 TIVC
회사 이름Tivic Health Systems Inc
상장일Nov 11, 2021
CEOErnst (Jennifer)
직원 수7
유형Ordinary Share
회계 연도 종료Nov 11
주소47685 Lakeview Blvd
도시FREMONT
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호94538
전화18882766888
웹사이트https://tivichealth.com/
종목 코드 TIVC
상장일Nov 11, 2021
CEOErnst (Jennifer)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음